CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs | MicrobiomeTrials← Back to trialsNCT07172256
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-05-07Est. Completion: 2031-02
Enrollment target: 30 participants Locations- Yale University, New Haven, Connecticut, United States
Other microbiome trials you might be interested in
Esophageal Squamous Cell CarcinomaImmunotherapyBiomarkers
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemora…
Fuzhou, ChinaEst. completion Dec 2027
Head and Neck CancerHead and Neck Squamous Cell CarcinomaParanasal Sinus NeoplasmsNasopharyngeal CarcinomaOropharyngeal Squamous Cell Carcinoma
Hypopharyngeal Cancer
Carcinoma of Larynx
Oral Squamous Cell Carcinoma
Salivary Gland Cancer
Adenoid Cystic Carcinoma
Prostate Cancer
Metastatic Castration Resistant Prostate Cancer
Background:
Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat,…
Bethesda, United StatesEst. completion Oct 1, 2036
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaLocally Recurrent Oropharyngeal Squamous Cell CarcinomaStage II Laryngeal Cancer AJCC v8Stage II Lip and Oral Cavity Cancer AJCC v8Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVA Laryngeal Cancer AJCC v8Stage IVA Lip and Oral Cavity Cancer AJCC v8Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVB Laryngeal Cancer AJCC v8Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with ca…
Tucson, United StatesEst. completion Feb 1, 2033